Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials

被引:0
|
作者
Lian, Jinrong [1 ]
Lin, Zhimin [1 ]
Li, Xiang [1 ]
Chen, Gang [1 ]
Wu, Depei [1 ]
机构
[1] Soochow Univ, Dept Clin Med, Affiliated Hosp 1, Suzhou, Jiangsu Provinc, Peoples R China
关键词
Zuranolone; Major depressive disorder; Safety; Efficacy; 2016 CLINICAL GUIDELINES; ANXIETY TREATMENTS; CANADIAN NETWORK; MANAGEMENT; ADULTS; MOOD;
D O I
10.1016/j.jad.2024.03.057
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To investigate the efficacy and safety of different dosage regimens of zuranolone in the treatment of patients with major depressive disorder (MDD). Methods: PubMed, Embase, The Cochrane Library and other databases were searched from inception until July 2019. Randomized controlled trials (RCTs) related to the efficacy and safety of zuranolone in the treatment of MDD were included. The data were extracted independently by 2 investigators and assessed the study quality by the Cochrane risk -of -bias tool. The primary outcome includes the 17 -item HAMILTON total score (HAMD-17) and the incidence of adverse events (AEs). Results: Six high -quality RCTs with 1593 patients were finally included in our analysis. Zuranolone group achieve a notable treatment effect at day15 in HAMD-17 compared with placebo group (MD = -2.69, 95 % CI: -4.45 to -0.94, P < 0.05). For safety, no significant differences existed in the proportion of patients with AEs between zuranolone with placebo (RR = 1.25, 95 % CI: 0.99 to 1.58, P = 0.06). Conclusion: Zuranolone has a significant efficacy in improving depressive symptoms in the short term and is positively correlated with the dosage administered. However, the efficacy of zuranolone decreased significantly when the time of administration was extended. Zuranolone demonstrated a controllable safety issue. But adverse effects increased as the dose of zuranolone was gradually increased to 50 mg.
引用
收藏
页码:206 / 215
页数:10
相关论文
共 50 条
  • [21] Meta Analysis of randomised controlled trials of Venlafaxine in the treatment of major depressive disorder
    Bauer, Michael
    Freemantle, N.
    Tharmanathan, P.
    [J]. NERVENARZT, 2007, 78 : 115 - 115
  • [22] Efficacy of inpatient psychotherapy for major depressive disorder: a meta-analysis of controlled trials
    Schefft, C.
    Guhn, A.
    Brakemeier, E. -L.
    Sterzer, P.
    Koehler, S.
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2019, 139 (04) : 322 - 335
  • [23] Efficacy and tolerability of zuranolone in patients with depression: a meta-analysis of randomized controlled trials
    Qiu, Youjia
    Tao, Yuchen
    Duan, Aojie
    Wei, Xingzhou
    Wang, Menghan
    Xie, Minjia
    Chen, Zhouqing
    Shang, Jing
    Wang, Zhong
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [24] Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials
    Wu, Hui-Zhen
    Cheng, Yuan
    Yu, Ding
    Li, Ji-Bin
    Jiang, Yun-Fa
    Zhu, Zhong-Ning
    [J]. HYPERTENSION IN PREGNANCY, 2022, 41 (02) : 126 - 138
  • [25] Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: A meta-analysis of randomized clinical trials
    Vis, PMJ
    van Baardewijk, M
    Einarson, TR
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (11) : 1798 - 1807
  • [26] A COST UTILITY ANALYSIS OF ZURANOLONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
    Kim, H. S.
    Cheng, S. Y.
    Ballreich, J.
    Levy, J.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S83 - S83
  • [27] Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial
    Clayton, Anita H.
    Lasser, Robert
    Parikh, Sagar, V
    Iosifescu, Dan, V
    Jung, Jungah
    Kotecha, Mona
    Forrestal, Fiona
    Jonas, Jeffrey
    Kanes, Stephen J.
    Doherty, James
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2023, 180 (09): : 676 - 684
  • [28] The effectiveness of mindfulness yoga on patients with major depressive disorder: a systematic review and meta-analysis of randomized controlled trials
    Miao, Chuyuan
    Gao, Yun
    Li, Xiaohua
    Zhou, Ying
    Chung, Joanne Wai-yee
    Smith, Graeme D.
    [J]. BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2023, 23 (01)
  • [29] Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials
    Maneeton, Narong
    Maneeton, Benchalak
    Srisurapanont, Manit
    Martin, Stephen D.
    [J]. BMC PSYCHIATRY, 2012, 12
  • [30] Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials
    Narong Maneeton
    Benchalak Maneeton
    Manit Srisurapanont
    Stephen D Martin
    [J]. BMC Psychiatry, 12